RecruitmentOSPREYNCT07290335
Optimizing Strategies to Maximize Patient Recruitment Yield
A study testing Positively-valenced message, Payment-inclusive message and Positively-valenced, payment-inclusive message in people with Recruitment, run by Emory University at 1 site in United States.
Trial summary
This platform trial aims to evaluate the effectiveness of different messaging strategies within a MyChart messaging program for research recruitment. MyChart is a patient portal system within the Electronic Medical Record (EMR), and messages can be sent directly to patients about research opportunities. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Recruitment
- What is being tested?
- Positively-valenced message, Payment-inclusive message and Positively-valenced, payment-inclusive message
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100,000 participants
- Where
- 1 siteUnited States
- Study dates
- 19 Feb 2026to Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All patients receiving messages via MyChart will be included
- Potential eligibility for a study using MyChart requirement based on the planned query/criteria for that study.
Who cannot join
- Minor
- Excluded from primary study that is recruiting participants.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Emory Healthcare System
Atlanta, Georgia, 30322
About this study
This platform trial aims to evaluate the effectiveness of different messaging strategies within a MyChart messaging program for research recruitment. MyChart is a patient portal system within the Electronic Medical Record (EMR), and messages can be sent directly to patients about research opportunities.
Read the detailed description
Recruitment of participants presents a significant and persistent bottle neck in the research process. Failure to reach participant enrollment targets may delay or halt study progression, wasting limited resources. Insufficient rates of participant accrual are the leading cause for termination among clinical trials with results posted on ClinicalTrials.gov. Additionally, studies must enroll representative samples to ensure generalizability and comply with NIH guidelines. Investigators often cite recruitment difficulties - including lack of interest, difficulty reaching specific populations, and limited resources - to explain failure to reach enrollment goals. However, these recruitment difficulties may not actually be due to a lack of willingness to participate among eligible patients. A national survey conducted by Harris Interactive in 2001 found that 85% of patients were either unaware or unsure that participation in a clinical trial was an option at the time of diagnosis. 75% of these patients said they would have been willing to enroll had they known it was possible. Innovation in recruitment is sorely needed to make recruitment more efficient and more representative.
In recent years, researchers have begun to leverage patient portals and electronic health records (EHRs) for recruitment. This method allows for engagement of broad populations within a health system in a cost-effective way. Emerging evidence of EHR recruitment shows promise. The researchers of this study have examined the use of EHR recruitment to identify and contact eligible patients via MyChart direct-to-patient messaging across a range studies within Emory Healthcare. Having completed a pilot program within the Emory system, this service is now available to all Emory investigators for whom MyChart recruitment is appropriate.
While the feasibility of MyChart messaging has been documented, little is known about best practices for how recruitment messages should be designed. There are, however, good reasons to believe that how messages are designed and framed may impact potential participants' responses to them.
This project is a platform trial that will allow for serial testing of various aspects of portal-based messaging. Consistent with platform trial design, the researchers will use a common set of outcome measures across various studies, and the portal-based messaging strategy allows for easy randomization (generally at the patient level) of patients to specific messaging approaches.
In the context of broader use of MyChart messaging, the researchers have designed this study to examine the impact of message design on patients' responses. Specifically, this study will examine the impact of including positively-valenced language that describes the value of the study and the impact of inclusion of information regarding any payments that participants will receive in the study. Both of these factors are ones that are grounded in behavioral economics and may be meaningful to potential participants.
The first proposed trial will involve randomly assigning patients who are identified as potentially eligible for studies using the MyChart recruitment mechanism to receive a recruitment message using 1 of 4 templates: 1) the current standard template; 2) a template with inclusion of positively-valenced language describing the study's value; 3) a template containing information about payment to participants; and 4) a template with both positively-valenced language and payment information. For all studies using the MyChart mechanism, all 4 messages will be created, and assignment will be done based on the last two digits of the patient's medical record number (MRN).
The primary endpoint is the rate at which individuals respond that they are interested in participating in the study to which they are invited. Additionally, this study will examine the non-response rate and the rate of individuals responding that they are not interested in the study. It will also track the rate at which individuals exposed to a MyChart recruitment message change their permission settings for contact about research opportunities. Study teams whose study invitations are used in this trial will be contacted about the rate of enrollment among patients who responded as "interested" to the message so that the researchers can estimate enrollment rate within each intervention group. Finally, select patients will participate in short interviews to understand their impressions of the message they were sent and their attitudes towards research more generally.
- Conditions
- Recruitment
- Being tested
- Baseline (control) message, Positively-valenced message, Payment-inclusive message, Positively-valenced, payment-inclusive message
- Keywords
- Research recruitment, Patient portal-based communication
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Baseline (control) messageBehavioural
The MyChart study recruitment program will send a message based on the current template, which is a brief message with a neutral tone.
Positively-valenced messageBehavioural
The MyChart study recruitment program will send a message based on a template that contains positively-valenced language related to the value/importance of the study.
Payment-inclusive messageBehavioural
The MyChart study recruitment program will send a message based on a template that includes more detailed information about participant payment.
Positively-valenced, payment-inclusive messageBehavioural
The MyChart study recruitment program will send a message based on a template that includes both positively-valenced language and detailed information about participant payment.
| Study group | Role | What they receive |
|---|---|---|
| Baseline (control) message | Active comparator | Patients in the Emory Healthcare system, who have not opted out of research contact, receiving MyChart messaging for research recruitment using the current standard template. Receives: Behavioral: Baseline (control) message |
| Positively-valenced message | Experimental | Patients in the Emory Healthcare system, who have not opted out of research contact, receiving MyChart messaging for research recruitment using a template with inclusion of positively-valenced language describing the study's value. Receives: Behavioral: Positively-valenced message |
| Payment-inclusive message | Experimental | Patients in the Emory Healthcare system, who have not opted out of research contact, receiving MyChart messaging for research recruitment using a template containing information about payment to participants. Receives: Behavioral: Payment-inclusive message |
| Positively-valenced, payment-inclusive message | Experimental | Patients in the Emory Healthcare system, who have not opted out of research contact, receiving MyChart messaging for research recruitment using a template with both positively-valenced language and payment information. Receives: Behavioral: Positively-valenced, payment-inclusive message |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of "interested" response to recruitment messages
The primary endpoint is the rate at which individuals respond that they are interested in participating in the study to which they are invited. The primary outcome is a binary variable of "interested" response.
Measured: Month 12
Secondary outcomes (6)
Rate of non-response
This study will examine the rate of non-response to recruitment messages.
Measured: Month 12
Rate of "not interested" responses
This study will examine the rate of individuals responding that they are not interested in the study.
Measured: Month 12
Rate of change in MyChart permissions to contact
This study will examine the rate at which individuals exposed to a MyChart recruitment message change their permission settings for contact about research opportunities.
Measured: Month 12
Rate of enrollment among "interested" patients
Study teams whose study invitations are used in this trial will be contacted about the rate of enrollment among patients who responded as "interested" to the message.
Measured: Month 12
Patient impressions on recruitment messages
Some patients will participate in short interviews to understand their impressions of the message they were sent. Qualitative data are collected during the interviews and there is not a standardized questionnaire or scale that will be used.
Measured: Month 12
Patient impressions on research in general
Some patients will participate in short interviews to understand their attitudes towards research more generally. Qualitative data are collected during the interviews and there is not a standardized questionnaire or scale that will be used.
Measured: Month 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Dec 2025
- Study start19 Feb 2026
- Primary completionApr 2027 (estimated)
- Study completionApr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for RecruitmentStudies of the same condition, open and under way.
- More trials run by Emory UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 100,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Emory University
- Sponsor type
- University, hospital or other
- Collaborators
- American Heart Association, Georgia Clinical & Translational Science Alliance, National Center for Advancing Translational Sciences (NCATS)
- Responsible party
- Principal investigator, Neal Dickert, Emory University
- Investigators
- Neal Dickert, MD, PhD, Principal investigator, Emory University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07290335
- Sponsor's protocol ID
- 2025P013508
- Other IDs
- UL1TR002378
- Acronym
- OSPREY
- Status last verified
- Feb 2026
- First submitted
- 15 Dec 2025
- Last updated
- 25 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Deidentified data will be available for sharing. This will include deidentified participant-level demographic characteristics, intervention assignment, and enrollment/non-enrollment status within the parent trial. This will include a de-identified data spreadsheet, readme file, and a data dictionary.
Study at a glance
From the registry record, last updated by the sponsor on 25 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optimizing Strategies to Maximize Patient Recruitment Yield
- ClinicalTrials.gov ID
- NCT07290335
- Acronym / sponsor ID
- OSPREY / 2025P013508
- Conditions
- Recruitment
- Keywords
- Research recruitment, Patient portal-based communication
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100,000 participants (estimated)
- Lead sponsor
- Emory UniversityUniversity, hospital or other
- Collaborators
- American Heart Association, Georgia Clinical & Translational Science Alliance, National Center for Advancing Translational Sciences (NCATS)
- Study start
- 19 Feb 2026 (actual)
- Primary completion
- Apr 2027 (estimated)
- Study completion
- Apr 2027 (estimated)
- First posted
- 18 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This platform trial aims to evaluate the effectiveness of different messaging strategies within a MyChart messaging program for research recruitment. MyChart is a patient portal system within the Electronic Medical Record (EMR), and messages can be sent directly to patients about research opportunities.
Detailed description
Recruitment of participants presents a significant and persistent bottle neck in the research process. Failure to reach participant enrollment targets may delay or halt study progression, wasting limited resources. Insufficient rates of participant accrual are the leading cause for termination among clinical trials with results posted on ClinicalTrials.gov. Additionally, studies must enroll representative samples to ensure generalizability and comply with NIH guidelines. Investigators often cite recruitment difficulties - including lack of interest, difficulty reaching specific populations, and limited resources - to explain failure to reach enrollment goals. However, these recruitment difficulties may not actually be due to a lack of willingness to participate among eligible patients. A national survey conducted by Harris Interactive in 2001 found that 85% of patients were either unaware or unsure that participation in a clinical trial was an option at the time of diagnosis. 75% of these patients said they would have been willing to enroll had they known it was possible. Innovation in recruitment is sorely needed to make recruitment more efficient and more representative.
In recent years, researchers have begun to leverage patient portals and electronic health records (EHRs) for recruitment. This method allows for engagement of broad populations within a health system in a cost-effective way. Emerging evidence of EHR recruitment shows promise. The researchers of this study have examined the use of EHR recruitment to identify and contact eligible patients via MyChart direct-to-patient messaging across a range studies within Emory Healthcare. Having completed a pilot program within the Emory system, this service is now available to all Emory investigators for whom MyChart recruitment is appropriate.
While the feasibility of MyChart messaging has been documented, little is known about best practices for how recruitment messages should be designed. There are, however, good reasons to believe that how messages are designed and framed may impact potential participants' responses to them.
This project is a platform trial that will allow for serial testing of various aspects of portal-based messaging. Consistent with platform trial design, the researchers will use a common set of outcome measures across various studies, and the portal-based messaging strategy allows for easy randomization (generally at the patient level) of patients to specific messaging approaches.
In the context of broader use of MyChart messaging, the researchers have designed this study to examine the impact of message design on patients' responses. Specifically, this study will examine the impact of including positively-valenced language that describes the value of the study and the impact of inclusion of information regarding any payments that participants will receive in the study. Both of these factors are ones that are grounded in behavioral economics and may be meaningful to potential participants.
The first proposed trial will involve randomly assigning patients who are identified as potentially eligible for studies using the MyChart recruitment mechanism to receive a recruitment message using 1 of 4 templates: 1) the current standard template; 2) a template with inclusion of positively-valenced language describing the study's value; 3) a template containing information about payment to participants; and 4) a template with both positively-valenced language and payment information. For all studies using the MyChart mechanism, all 4 messages will be created, and assignment will be done based on the last two digits of the patient's medical record number (MRN).
The primary endpoint is the rate at which individuals respond that they are interested in participating in the study to which they are invited. Additionally, this study will examine the non-response rate and the rate of individuals responding that they are not interested in the study. It will also track the rate at which individuals exposed to a MyChart recruitment message change their permission settings for contact about research opportunities. Study teams whose study invitations are used in this trial will be contacted about the rate of enrollment among patients who responded as "interested" to the message so that the researchers can estimate enrollment rate within each intervention group. Finally, select patients will participate in short interviews to understand their impressions of the message they were sent and their attitudes towards research more generally.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Baseline (control) message | Active comparator | Behavioral: Baseline (control) messagePatients in the Emory Healthcare system, who have not opted out of research contact, receiving MyChart messaging for research recruitment using the current standard template. |
| Positively-valenced message | Experimental | Behavioral: Positively-valenced messagePatients in the Emory Healthcare system, who have not opted out of research contact, receiving MyChart messaging for research recruitment using a template with inclusion of positively-valenced language describing the study's value. |
| Payment-inclusive message | Experimental | Behavioral: Payment-inclusive messagePatients in the Emory Healthcare system, who have not opted out of research contact, receiving MyChart messaging for research recruitment using a template containing information about payment to participants. |
| Positively-valenced, payment-inclusive message | Experimental | Behavioral: Positively-valenced, payment-inclusive messagePatients in the Emory Healthcare system, who have not opted out of research contact, receiving MyChart messaging for research recruitment using a template with both positively-valenced language and payment information. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- All patients receiving messages via MyChart will be included
- Potential eligibility for a study using MyChart requirement based on the planned query/criteria for that study.
Key exclusion criteria (2 listed)
- Minor
- Excluded from primary study that is recruiting participants.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Baseline (control) messageThe MyChart study recruitment program will send a message based on the current template, which is a brief message with a neutral tone. | Behavioural | Baseline (control) message |
| Positively-valenced messageThe MyChart study recruitment program will send a message based on a template that contains positively-valenced language related to the value/importance of the study. | Behavioural | Positively-valenced message |
| Payment-inclusive messageThe MyChart study recruitment program will send a message based on a template that includes more detailed information about participant payment. | Behavioural | Payment-inclusive message |
| Positively-valenced, payment-inclusive messageThe MyChart study recruitment program will send a message based on a template that includes both positively-valenced language and detailed information about participant payment. | Behavioural | Positively-valenced, payment-inclusive message |
Primary outcome
Rate of "interested" response to recruitment messages
Time frame: Month 12
The primary endpoint is the rate at which individuals respond that they are interested in participating in the study to which they are invited. The primary outcome is a binary variable of "interested" response.
6 secondary outcomes
Rate of non-response
Time frame: Month 12
Rate of "not interested" responses
Time frame: Month 12
Rate of change in MyChart permissions to contact
Time frame: Month 12
Rate of enrollment among "interested" patients
Time frame: Month 12
Patient impressions on recruitment messages
Time frame: Month 12
Patient impressions on research in general
Time frame: Month 12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Feb 2026.
- Individual participant dataSharing planned: Yes. Deidentified data will be available for sharing. This will include deidentified participant-level demographic characteristics, intervention assignment, and enrollment/non-enrollment status within the parent trial. This will include a de-identified data spreadsheet, readme file, and a data dictionary.
Related trials for Recruitment
RecruitingObservational study
Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes
Granuloma, Granulomatous Disease, Chronic
Not yet recruiting
The Hemodynamic Impact of High-frequency Oscillatory Ventilation and Periodic Sighs in Preterm Infants
Preterm, Respiratory Distress Syndrome in Premature Infant
Active, not recruiting
Stepwise PEEP vs Sustained Inflation in Bariatric Surgery Patients
Recruitment, Bariatric Surgery Candidate
Enrolling by invitation
AI-Guided Multi-Electrode Transcutaneous Spinal Cord Stimulation for Gait Rehabilitation in People With Spinal Cord Injury or Stroke
Spinal Cord Injuries (SCI)
Not yet recruiting
Bedside Assessment of Right Ventricular Output Lying in Prone Or Supine
Right Ventricular Function, Prone Position
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Neal Dickert, MD, PhD principal investigator
Emory University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Positively-valenced message, Payment-inclusive message and Positively-valenced, payment-inclusive message in people with Recruitment, run by Emory University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Neal Dickert, MD, PhD ((404) 712-6834, njr@emory.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of "interested" response to recruitment messages (time frame: Month 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2026.